During the corresponding time, Precipio Inc recorded a revenue increase by 24.18 % year on year, sequentially revenue grew by 4.62 %. While revenue at the Precipio Inc 's corporate clients
Precipio Inc's Comment on Sales, Marketing and Customers
HemeScreen technology offers diagnostic panels for Myeloproliferative Neoplasms, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Cytopenia, and BCR-ABL, with additional panels such as BCR-ABL1 and Bloodhound MPN assays introduced in 2024. These assays provide lower detection limits and quantitative results, supported by complementary analysis software (BHAS) designed to streamline laboratory workflows. The technology reduces test turnaround time from two weeks to two days and aims to improve the economics of blood cancer diagnostic testing while decreasing technician time. Laboratories benefit from using a single platform for multiple genes, which lowers expertise requirements, reduces batch sizes and turnaround times, enhances clinical service, and increases revenue.
IV-Cell is a proprietary cell culture media developed by Precipio that enables simultaneous culturing of all four hematopoietic cell lineages: myeloid, B-cell, T-cell, and plasma cells. IV-Cell addresses diagnostic errors associated with reliance on oncologist clinical suspicion and has demonstrated superior results compared to MarrowMax. This media has been validated in Precipio's laboratory.
As the landscape of cancer diagnostics continues to evolve, Precipio, Inc. has positioned itself at the forefront of innovative testing solutions. The company, known for its specialty diagnostics focused on hematologic cancers, recently announced the expansion of its Bloodhound MPN panel to include CALR mutation subtyping. This development promises significant enhancements in the ability of laboratories to deliver comprehensive and accurate diagnostic data, thereby empowering clinicians to make more informed treatment decisions for their patients. Understanding the CALR Mutation and Its ImportanceThe CALR (Calreticulin) mutation is one of the key genetic alterations identified in myeloproliferative neoplasms...
Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO), recently shared its thoughts and reflections on the year 2023 while expressing its optimism and expectations for the upcoming year, 2024. This article delves into the highlights from the press release, providing insights into Precipio s accomplishments, challenges faced, and its vision for the future. Reflecting on a Productive Year: Precipio Management expressed satisfaction with the company s performance throughout 2023. They highlighted several key achievements, one of which was the successful launch of their revolutionary liquid biopsy technology. This groundbreaking innovation has significantly improved the accuracy a...
Precipio Inc’s Comment on Sales, Marketing and Customers
HemeScreen technology offers diagnostic panels for Myeloproliferative Neoplasms, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Cytopenia, and BCR-ABL, with additional panels such as BCR-ABL1 and Bloodhound MPN assays introduced in 2024. These assays provide lower detection limits and quantitative results, supported by complementary analysis software (BHAS) designed to streamline laboratory workflows. The technology reduces test turnaround time from two weeks to two days and aims to improve the economics of blood cancer diagnostic testing while decreasing technician time. Laboratories benefit from using a single platform for multiple genes, which lowers expertise requirements, reduces batch sizes and turnaround times, enhances clinical service, and increases revenue.
IV-Cell is a proprietary cell culture media developed by Precipio that enables simultaneous culturing of all four hematopoietic cell lineages: myeloid, B-cell, T-cell, and plasma cells. IV-Cell addresses diagnostic errors associated with reliance on oncologist clinical suspicion and has demonstrated superior results compared to MarrowMax. This media has been validated in Precipio's laboratory.
Sources:
Precipio inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Precipio inc’s corporate clients.
For your research, we’ve provided 9 tables on Precipio inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
173.29 %